title: Intestinal permeability--a new target for disease prevention and therapy.
abstract: Data are accumulating that emphasize the important role of the intestinal barrier and intestinal permeability for health and disease. However, these terms are poorly defined, their assessment is a matter of debate, and their clinical significance is not clearly established. In the present review, current knowledge on mucosal barrier and its role in disease prevention and therapy is summarized. First, the relevant terms 'intestinal barrier' and 'intestinal permeability' are defined. Secondly, the key element of the intestinal barrier affecting permeability are described. This barrier represents a huge mucosal surface, where billions of bacteria face the largest immune system of our body. On the one hand, an intact intestinal barrier protects the human organism against invasion of microorganisms and toxins, on the other hand, this barrier must be open to absorb essential fluids and nutrients. Such opposing goals are achieved by a complex anatomical and functional structure the intestinal barrier consists of, the functional status of which is described by 'intestinal permeability'. Third, the regulation of intestinal permeability by diet and bacteria is depicted. In particular, potential barrier disruptors such as hypoperfusion of the gut, infections and toxins, but also selected over-dosed nutrients, drugs, and other lifestyle factors have to be considered. In the fourth part, the means to assess intestinal permeability are presented and critically discussed. The means vary enormously and probably assess different functional components of the barrier. The barrier assessments are further hindered by the natural variability of this functional entity depending on species and genes as well as on diet and other environmental factors. In the final part, we discuss selected diseases associated with increased intestinal permeability such as critically illness, inflammatory bowel diseases, celiac disease, food allergy, irritable bowel syndrome, and--more recently recognized--obesity and metabolic diseases. All these diseases are characterized by inflammation that might be triggered by the translocation of luminal components into the host. In summary, intestinal permeability, which is a feature of intestinal barrier function, is increasingly recognized as being of relevance for health and disease, and therefore, this topic warrants more attention.
authors.forename: Stephan C
authors.initials: SC
authors.lastname: Bischoff
authors.forename: Giovanni
authors.initials: G
authors.lastname: Barbara
authors.forename: Wim
authors.initials: W
authors.lastname: Buurman
authors.forename: Theo
authors.initials: T
authors.lastname: Ockhuizen
authors.forename: Jörg-Dieter
authors.initials: JD
authors.lastname: Schulzke
authors.forename: Matteo
authors.initials: M
authors.lastname: Serino
authors.forename: Herbert
authors.initials: H
authors.lastname: Tilg
authors.forename: Alastair
authors.initials: A
authors.lastname: Watson
authors.forename: Jerry M
authors.initials: JM
authors.lastname: Wells
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D016638:Critical Illness; D004032:Diet; D005234:Fatty Liver / Q000378:metabolism; D006632:Histamine / Q000378:metabolism; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000378:metabolism; D007413:Intestinal Mucosa / Q000276:immunology / Q000378:metabolism*; D007422:Intestines / Q000276:immunology / Q000382:microbiology; D017136:Ion Transport; D009765:Obesity / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism; D010539:Permeability; D056692:Prebiotics; D019936:Probiotics / Q000008:administration & dosage; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism
chemical_list: D015415:Biomarkers; D056692:Prebiotics; D043884:Receptor, Cannabinoid, CB1; D012701:Serotonin; D006632:Histamine; D010447:Peptide Hydrolases